Amy Beveridge
Impact in
- Infectious Diseases top 0.1%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 detection and testing
- Health top 0.2%
- Vaccine Coverage and Hesitancy
Papers in
-
- SARS-CoV-2 and COVID-19 Research 10
- COVID-19 Clinical Research Studies 4
- SARS-CoV-2 detection and testing 1
-
- Immunotherapy and Immune Responses 2
- Journals
- The Lancet (5 papers)Nature Medicine (4 papers)The Lancet Digital Health (1 paper)The Lancet Infectious Diseases (1 paper)Cell (1 paper)
- Partner nations
- United KingdomFranceChina
In The Last Decade
Amy Beveridge
12 papers receiving 8.8k citations
Amy Beveridge's Hit Papers
Peers
Comparison fields: 5 of 133
- Infectious Diseases 6.9k
- Health 1.7k
- Modeling and Simulation 785
- Animal Science and Zoology 566
- Immunology 941
Countries citing papers authored by Amy Beveridge
This map shows the geographic impact of Amy Beveridge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Beveridge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Beveridge more than expected).
Fields of papers citing papers by Amy Beveridge
This network shows the impact of papers produced by Amy Beveridge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Beveridge. The network helps show where Amy Beveridge may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Hit paper breakdown → | 2020 | 3621 |
| 2 | Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Hit paper breakdown → | 2020 | 1899 |
| 3 | Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials Hit paper breakdown → | 2021 | 867 |
| 4 | Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection Hit paper breakdown → | 2021 | 865 |
| 5 | 2020 | 469 | |
| 6 | Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study Hit paper breakdown → | 2022 | 335 |
| 7 | 2020 | 281 | |
| 8 | 2020 | 251 | |
| 9 | A blood atlas of COVID-19 defines hallmarks of disease severity and specificity Hit paper breakdown → | 2022 | 209 |
| 10 | 2021 | 182 | |
| 11 | 2022 | 64 | |
| 12 | 2022 | 29 |
About Amy Beveridge
Amy Beveridge is a scholar working on Infectious Diseases, Immunology, Modeling and Simulation, Animal Science and Zoology and Neurology, having authored 12 papers that have together received 9.1k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (10 papers), COVID-19 Clinical Research Studies (4 papers), Immunotherapy and Immune Responses (2 papers), Animal Virus Infections Studies (1 paper), vaccines and immunoinformatics approaches (1 paper), COVID-19 epidemiological studies (1 paper), SARS-CoV-2 detection and testing (1 paper) and Long-Term Effects of COVID-19 (1 paper). The work is most often cited by research in Infectious Diseases (6.9k citations), Health (1.7k citations), Modeling and Simulation (785 citations), Animal Science and Zoology (566 citations) and Immunology (941 citations). Amy Beveridge has collaborated with scholars based in United Kingdom, France and China. Their work appears in journals such as The Lancet, Nature Medicine, The Lancet Digital Health, The Lancet Infectious Diseases and Cell.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.